Percutaneous Coronary Intervention

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2008-04-23

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: in-stent thrombosis. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.


Scope

  • Review of the acute coronary syndromes (ACS) - the indication that drives the PCI market.
  • Opinion leader commentary on guideline developments and key clinical trials.
  • Review of the key drug classes used in conjunction with PCI and the current opinion on facilitated PCI.
  • Opinion leader discussion of currently marketed stents, key clinical trials in stents, and the evolution from bare metal to drug eluting stents.


    • Report Highlights
    Since the introduction of PCI the procedure rate has increased dramatically making it one of the most common interventional procedures for heart disease. Use of PCI differs across the major markets, with this more aggressive revascularization strategy receiving greatest uptake in the United States, where coronary artery disease is most prevalent.

    Evidence that facilitated PCI improves clinical outcomes remains inconclusive, although opinion leaders consider the premature interruption of ASSENT-4 to advise against facilitation with thrombolytics; the ACC/AHA guidelines suggest facilitation only in high risk patients, whereas the ESC say they find no evidence to recommend it at all.

    While drug eluting stents have been successful in reducing restenosis rates from 20-30% to single digits, there have been safety scares over a new problem: in-stent thrombosis. Cordis's Cypher and Boston Scientific's Taxus have received some unfavourable press, but physicians are still enthusiastic about Abbott's new stent, Xience.


    Reasons to Purchase

  • Understand the PCI market, the driving indications and the drug classes prescribed in PCI patients.
  • Gain physician opinion on current treatment practice and how it might evolve.
  • Understand the negative publicity which has caused the robust drug eluting stent market to falter.

    • Table of Contents

    Other users found this report page using the following search terms: Percutaneous Coronary Intervention pci atherosclerosis stent drug eluting stent bare metal stent nstemi pci coronary definition percutaneous intervention interventions market procedures primary

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.